Richard Roberts, MD
Allergy & Immunology · Charlotte, NCNPI 1093759243
Payments from drug & device makers
Across 396 payments — averaging $24.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$1K
- Sanofi$701
- Novartis$603
- Pfizer$506
- Regeneron Healthcare Solutions, Inc.$430
- plus $5K from 35 others
What the payments were for
- Consulting fees$701%
- Food & beverage$9,79099%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 73 | $1,945 |
| GSK | 64 | $1,074 |
| Sanofi | 28 | $701 |
| Novartis | 17 | $603 |
| Pfizer | 36 | $506 |
| Regeneron Healthcare Solutions, Inc. | 19 | $430 |
| Genentech USA, Inc. | 16 | $371 |
| Amgen(2 entities) | 12 | $365 |
| Alk-abello, Inc | 12 | $322 |
| Pharming Healthcare, Inc. | 7 | $291 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $246 |
| Regeneron | 2 | $219 |
| Optinose US, Inc. | 4 | $214 |
| ARS Pharmaceuticals Operations, Inc. | 4 | $210 |
| Stryker | 3 | $191 |
| Grifols USA, LLC | 12 | $190 |
| CSL Behring | 8 | $181 |
| Covis Pharma GmbH | 11 | $167 |
| Biocryst US Sales Co., LLC | 6 | $160 |
| Phadia US Inc. | 2 | $154 |
| Kaleo, Inc. | 9 | $148 |
| LEO Pharma Inc. | 1 | $125 |
| Ionis Pharmaceuticals, Inc. | 1 | $120 |
| BD | 1 | $114 |
| AbbVie | 6 | $110 |
| Circassia Inc. | 1 | $98 |
| Hikma Pharmaceuticals USA | 5 | $78 |
| Boehringer Ingelheim | 3 | $75 |
| ADMA Biomanufacturing LLC | 3 | $70 |
| Aytu Biopharma, Inc. | 4 | $68 |
| Incyte Corporation | 3 | $59 |
| Octapharma USA, Inc. | 1 | $42 |
| Mylan Specialty L.p. | 2 | $34 |
| Vifor Pharma, Inc. | 1 | $30 |
| Siemens Medical Solutions USA, Inc. | 1 | $30 |
| Blueprint Medicines Corporation | 2 | $30 |
| Galderma Laboratories, L.p. | 1 | $23 |
| Invivyd Inc | 1 | $21 |
| Dermavant Sciences, Inc. | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Organon | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XOLAIR$255
- DUPIXENT$219
- TEZSPIRE$138
- NEFFY$133
- N/A$129
- Xhance$125
- ADBRY$125
- NUCALA$122
- DAWNZERA$120
- Rhapsido$120
- WAYRILZ$112
- PRE-PEN$109
- Histatrol (histamine phosphate)$109
- Timothy Grass (phleum pratense)$109
- Dust mite (D. farinae)$109
- Alternaria alternate (Alternaria tenuis)$109
How this compares
$9,860 in reported general payments places this provider in the 60th percentile of 140 allergy & immunology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CutaquigImmun Glob G(Igg)-Hipp/Maltose | 13 | $124,839 |
| XembifyImmune Globulin,gamma(Igg)klhw | 14 | $101,705 |
| Gammagard S-DImmun Glob G/Gly/Gluc/Iga 0-50 | 19 | $96,030 |
| XolairOmalizumab | 35 | $95,034 |
| Dupixent PenDupilumab | 25 | $94,329 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 17 | $78,607 |
| TezspireTezepelumab-Ekko | 11 | $45,534 |
| Breo ElliptaFluticasone/Vilanterol | 46 | $30,946 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $23,297 |
| Spiriva RespimatTiotropium Bromide | 24 | $15,449 |
| SymbicortBudesonide/Formoterol Fumarate | 34 | $11,505 |
| Advair DiskusFluticasone Propion/Salmeterol | 28 | $7,693 |
| Arnuity ElliptaFluticasone Furoate | 21 | $6,698 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 17 | $5,641 |
| Azelastine Hcl | 144 | $5,438 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Grifols USA, LLCXembify, Gamunex-C | $190 | $180,31231 claims |
| Octapharma USA, Inc.Cutaquig | $42 | $124,83913 claims |
| GSKBreo Ellipta, Trelegy Ellipta, Arnuity Ellipta | $1,074 | $60,94196 claims |
| AstraZenecaTezspire, Symbicort | $1,945 | $57,03945 claims |
| Boehringer IngelheimSpiriva Respimat | $75 | $15,44924 claims |
| Hikma Pharmaceuticals USAEpinephrine | $78 | $3,95118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 140 allergy & immunology providers in North Carolina.
Other allergy & immunology in Charlotte
- Maeve OconnorCharlotte$2.2M
- Roopen PatelCharlotte$391K
- John NorrisCharlotte$198K
- Jennifer CaicedoCharlotte$174K
- Vandana PatelCharlotte$105K
- Richard CollinsCharlotte$28K
- Shannon ChadhaCharlotte$22K
- Emily LangleyCharlotte$21K
- Bailee GilchristCharlotte$20K
- Susan HungnessCharlotte$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.